Your browser doesn't support javascript.
loading
Targeting isoaspartate-modified Aß rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathology.
Gnoth, Kathrin; Piechotta, Anke; Kleinschmidt, Martin; Konrath, Sandra; Schenk, Mathias; Taudte, Nadine; Ramsbeck, Daniel; Rieckmann, Vera; Geissler, Stefanie; Eichentopf, Rico; Barendrecht, Susan; Hartlage-Rübsamen, Maike; Demuth, Hans-Ulrich; Roßner, Steffen; Cynis, Holger; Rahfeld, Jens-Ulrich; Schilling, Stephan.
Afiliação
  • Gnoth K; Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle (Saale), Germany.
  • Piechotta A; Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle (Saale), Germany.
  • Kleinschmidt M; Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle (Saale), Germany.
  • Konrath S; Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle (Saale), Germany.
  • Schenk M; Present address: Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Taudte N; Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle (Saale), Germany.
  • Ramsbeck D; Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle (Saale), Germany.
  • Rieckmann V; Present address: PerioTrap Pharmaceuticals GmbH, Halle (Saale), Germany.
  • Geissler S; Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle (Saale), Germany.
  • Eichentopf R; Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle (Saale), Germany.
  • Barendrecht S; Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle (Saale), Germany.
  • Hartlage-Rübsamen M; Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle (Saale), Germany.
  • Demuth HU; Present address: Fraunhofer Center for Chemical-Biotechnological Processes CBP, Leuna, Germany.
  • Roßner S; Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle (Saale), Germany.
  • Cynis H; Paul Flechsig Institute of Brain Research, Leipzig University, Leipzig, Germany.
  • Rahfeld JU; Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle (Saale), Germany.
  • Schilling S; Paul Flechsig Institute of Brain Research, Leipzig University, Leipzig, Germany.
Alzheimers Res Ther ; 12(1): 149, 2020 11 14.
Article em En | MEDLINE | ID: mdl-33189132
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos beta-Amiloides / Doença de Alzheimer Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos beta-Amiloides / Doença de Alzheimer Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article